Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?

In the past several decades, innovative research in cancer biology and immunology has contributed to novel therapeutics, such as targeted therapy and immunotherapy, which have transformed the management of patients with melanoma. Despite the remarkable therapeutic outcomes of targeted treatments tar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huihua Zeng, Fen Liu, Hairong Zhou, Changchun Zeng
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	MAPK melanoma targeted therapy immunotherapy resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c6c121b0e76045d8b48f1af45349f876
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6c121b0e76045d8b48f1af45349f876
record_format	dspace
spelling	oai:doaj.org-article:c6c121b0e76045d8b48f1af45349f8762021-11-04T06:04:32ZIndividualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?2234-943X10.3389/fonc.2021.775100https://doaj.org/article/c6c121b0e76045d8b48f1af45349f8762021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.775100/fullhttps://doaj.org/toc/2234-943XIn the past several decades, innovative research in cancer biology and immunology has contributed to novel therapeutics, such as targeted therapy and immunotherapy, which have transformed the management of patients with melanoma. Despite the remarkable therapeutic outcomes of targeted treatments targeting MAPK signaling and immunotherapy that suppresses immune checkpoints, some individuals acquire therapeutic resistance and disease recurrence. This review summarizes the current understanding of melanoma genetic variations and discusses individualized melanoma therapy options, particularly for advanced or metastatic melanoma, as well as potential drug resistance mechanisms. A deeper understanding of individualized treatment will assist in improving clinical outcomes for patients with cutaneous melanoma.Huihua ZengFen LiuHairong ZhouChangchun ZengFrontiers Media S.A.articleMAPKmelanomatargeted therapyimmunotherapyresistanceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	MAPK melanoma targeted therapy immunotherapy resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	MAPK melanoma targeted therapy immunotherapy resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Huihua Zeng Fen Liu Hairong Zhou Changchun Zeng Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?
description	In the past several decades, innovative research in cancer biology and immunology has contributed to novel therapeutics, such as targeted therapy and immunotherapy, which have transformed the management of patients with melanoma. Despite the remarkable therapeutic outcomes of targeted treatments targeting MAPK signaling and immunotherapy that suppresses immune checkpoints, some individuals acquire therapeutic resistance and disease recurrence. This review summarizes the current understanding of melanoma genetic variations and discusses individualized melanoma therapy options, particularly for advanced or metastatic melanoma, as well as potential drug resistance mechanisms. A deeper understanding of individualized treatment will assist in improving clinical outcomes for patients with cutaneous melanoma.
format	article
author	Huihua Zeng Fen Liu Hairong Zhou Changchun Zeng
author_facet	Huihua Zeng Fen Liu Hairong Zhou Changchun Zeng
author_sort	Huihua Zeng
title	Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?
title_short	Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?
title_full	Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?
title_fullStr	Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?
title_full_unstemmed	Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?
title_sort	individualized treatment strategy for cutaneous melanoma: where are we now and where are we going?
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/c6c121b0e76045d8b48f1af45349f876
work_keys_str_mv	AT huihuazeng individualizedtreatmentstrategyforcutaneousmelanomawherearewenowandwherearewegoing AT fenliu individualizedtreatmentstrategyforcutaneousmelanomawherearewenowandwherearewegoing AT hairongzhou individualizedtreatmentstrategyforcutaneousmelanomawherearewenowandwherearewegoing AT changchunzeng individualizedtreatmentstrategyforcutaneousmelanomawherearewenowandwherearewegoing
_version_	1718445175486808064

Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?

Ejemplares similares